000056361 001__ 56361
000056361 005__ 20161006102716.0
000056361 0247_ $$2doi$$a10.1093/infdis/jiv503
000056361 0248_ $$2sideral$$a93909
000056361 037__ $$aART-2016-93909
000056361 041__ $$aeng
000056361 100__ $$0(orcid)0000-0001-7897-9173$$aAguiló Anento, Juan Ignacio$$uUniversidad de Zaragoza
000056361 245__ $$aPulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism.
000056361 260__ $$c2016
000056361 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056361 5203_ $$aSome of the most promising novel tuberculosis vaccine strategies currently under development are based on respiratory vaccination, mimicking the natural route of infection. In this work, we have compared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse strain, a model in which parenterally administered BCG vaccine does not protect against tuberculosis. Our data show that intranasally but not subcutaneously administered BCG confers robust protection against pulmonary tuberculosis challenge. In addition, our results indicate that pulmonary vaccination triggers a Mycobacterium tuberculosis–specific mucosal immune response orchestrated by interleukin 17A (IL-17A). Thus, IL-17A neutralization in vivo reduces protection and abrogates M. tuberculosis–specific immunoglobulin A (IgA) secretion to respiratory airways and lung expression of polymeric immunoglobulin receptor induced following intranasal vaccination. Together, our results demonstrate that pulmonary delivery of BCG can overcome the lack of protection observed when BCG is given parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tuberculosis-endemic countries, where intradermally administered BCG has inefficient effectiveness against pulmonary tuberculosis.
000056361 536__ $$9info:eu-repo/grantAgreement/EUR/H2020/TBVAC2020-643381$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 TBVAC2020 643381$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P
000056361 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056361 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000056361 700__ $$0(orcid)0000-0002-5748-6078$$aÁlvarez Arguedas, Samuel$$uUniversidad de Zaragoza
000056361 700__ $$0(orcid)0000-0001-7866-2803$$aUranga Maíz, Santiago
000056361 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova , Dessislava Vaneva
000056361 700__ $$0(orcid)0000-0002-2787-9671$$aMonzón Garcés, Marta$$uUniversidad de Zaragoza
000056361 700__ $$0(orcid)0000-0002-7173-7216$$aBadiola Díez, Juan José$$uUniversidad de Zaragoza
000056361 700__ $$0(orcid)0000-0003-2993-5478$$aMartín Montañés, Carlos$$uUniversidad de Zaragoza
000056361 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDepartamento de Patología Animal$$cSanidad Animal
000056361 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDepartamento de Microbiología, Medicina Preventiva y Salud Pública$$cMicrobiología
000056361 773__ $$g213, 5 (2016), 831-839$$pJ. infect. dis.$$tJOURNAL OF INFECTIOUS DISEASES$$x0022-1899
000056361 8564_ $$s1642484$$uhttp://zaguan.unizar.es/record/56361/files/texto_completo.pdf$$yPostprint
000056361 8564_ $$s48552$$uhttp://zaguan.unizar.es/record/56361/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000056361 909CO $$ooai:zaguan.unizar.es:56361$$particulos$$pdriver
000056361 951__ $$a2016-09-15-09:52:23
000056361 980__ $$aARTICLE